GenSight Biologics S.A. (GSGTF)

0.4500 0.0000 (0.00%) At close: 12:14PM EDT

GenSight Biologics S.A.

74, rue du Faubourg Saint-Antoine
Paris 75012
France
33 1 76 21 72 20
https://www.gensight-biologics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 16

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jose-Alain Sahel M.D., Ph.D.	Scientific Founder, Vice Chairman of Scientific Advisory Board & Board Observer	N/A	N/A	N/A
Dr. Luk H. Vandenberghe M.D., Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Constance L. Cepko Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Ivan Tortet	Interim Chief Financial Officer	N/A	N/A	1966
Mr. Scott Jeffers	Chief Technical Officer	N/A	N/A	N/A
Dr. Barrett Katz CMO, M.B.A., M.D.	Consultant	N/A	N/A	1951
Dr. Magali Taiël M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Marion Ghibaudo	Chief Technical Officer of Medical Device	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.

Corporate Governance

GenSight Biologics S.A.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.